Novo Nordisk – a platinum sponsor of the Joint Congress of ESPE and ESE 2025.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. For information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Find us on booth E28 in the exhibition hall E.
All further details below will be available on the Congress webpage too.
Congress activities
Sunday, 11 May 2025, 12:50 – 14:05, Hall D4
Perspectives on GHD Treatment – Long-term Data and Transition Management. – A Novo Nordisk sponsored satellite symposium.
Chair: Prof. Beverly MK Biller, USA
Welcome and Introduction
Chair: Prof. Beverly MK Biller, USA
Once-weekly Somapacitan in GHD: 7 Years Data from REAL 3
Tadej Battelino, Slovenia
Patient Journey with Somapacitan in GHD
Aristides Maniatis, USA
Transition Management in GHD: Experiences from the USA and Italy
Beverly MK Biller, USA & Natascia Di Iorgi, Italy
Q&A
All Faculty
Closing
Beverly MK Biller, USA
Monday, 12 May 2025, 13:00-14:30, Room C1
Managing obesity: A lifelong perspective from childhood to adulthood. – A Novo Nordisk sponsored satellite symposium.
Chair: Mikael Rydén, Sweden
Welcome and Introduction
Mikael Rydén, Sweden
Preventing the path ahead: Managing obesity and related complications in childhood
Antje Körner, Germany
Panel Discussion
All Faculty
Obesity and CV health: Navigating risks across generations
Morten Böttcher, Denmark
Panel Discussion
All Faculty
Audience Q&A and closing
All Faculty
